(2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid,
oxamflatin,
oxamflatin,
151720-43-3,
(2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid,
(E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide,
(2E)-5-[3-(Phenylsulfonylamino)phenyl]-pent-2-en-4-ynohydroxamic acid,
NSC729360,
NCGC00165855-01,
AC1NS4N2,
CHEMBL98245,
I14-11718,
SCHEMBL1232655,
SCHEMBL1232657,
2-Penten-4-ynamide, (2E)-,
CHEBI:93779,
DTXSID40417739,
QRPSQQUYPMFERG-LFYBBSHMSA-N,
BCP20651,
EX-A1442,
ZINC3826235,
1971AH,
MFCD00949087,
Oxamflatin, >=98% (HPLC), solid,
CCG-208700,
CS-6980,
NSC-729360,
HY-102033,
RT-014872,
Oxamflatin,151720-43-3,,Metacept 3Oxamflatin,
A809210,
J-008835,
BRD-K14221870-001-01-6,
N-Hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2E-penten-4-ynamide,
(2E)-5-[3-(Phenylsulfonylamino)phenyl]-2-penten-4-ynehydroximic acid,
(2E)-N-Hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2-penten-4-ynamide,
(E)-N-oxidanyl-5-[3-(phenylsulfonylamino)phenyl]pent-2-en-4-ynamide,
5OK,
D03YVR,
C17H14N2O4S,
CHEBI:258842,
CID5353852,
C100692,
(2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid,